Literature DB >> 16300908

A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells.

Elena M Glinka1, Eweline F Edelweiss, Alexander M Sapozhnikov, Sergey M Deyev.   

Abstract

Tumor-targeted vectors with controllable expression of therapeutic genes and specific antitumor antibodies are promising tools for the reduction of malignant tumors. Here we describe a new plasmid for the eukaryotic expression of an anti-HER2/neu mini-antibody-barnase fusion protein (4D5 scFv-barnase-His(5)) with an NH(2)-terminal leader peptide. The 4D5 scFv-barnase-His(5) gene was placed downstream of the tetracycline responsive-element minimal promoter in the vector using the Tet-Off gene-expression system. The Bacillus amyloliquefaciens ribonuclease barnase is toxic for the host cells. To overcome this problem, barstar gene under its own minimal cytomegalovirus promoter was used in designed vector. Barstar inhibits the background level of barnase in the cells in the presence of tetracycline in culture medium. The HEK 293T cells were transfected with the designed vector, and the 4D5 scFv-barnase-His(5) fusion protein was identified by anti-barnase antibodies in cell culture medium and after purification from cell lysates using metal-affinity chromatography. The overexpression of the anti-HER2/neu mini-antibody-barnase fusion protein decreased the intensity of fluorescence of HEK 293T cells co-transfected with the generated plasmid and a plasmid containing the gene of enhanced green fluorescent protein (pEGFP-N1), in comparison with the intensity of fluorescence of HEK 293T cells transfected with pEGFP-N1, in the absence of tetracycline in the medium. The effect of the 4D5 scFv-barnase-His(5) on EGFP fluorescence indicates that the introduced barnase functions as a ribonuclease inside the cells. The anti-HER2/neu mini-antibody could be used to deliver barnase to HER2/neu-positive cells and provide its penetration into the target cells, as HER2/neu is a ligand-internalizing receptor. This expression vector has potential applications to both gene and antibody therapies of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16300908     DOI: 10.1016/j.gene.2005.06.042

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  11 in total

Review 1.  Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor.

Authors:  Elena M Glinka
Journal:  Tumour Biol       Date:  2015-04-01

2.  Construction of the plasmid coding for the expression of the EGFP-M-IL-2(88Arg, 125Ala) fusion protein and the anti-tumor effects exerted by the fusion protein in HeLa-60 cells.

Authors:  Guangcan Shao; Dongmeng Qian; Haitao Wang; Zhiyong Yan; Ming Hu; Tongmei Wang; Bin Wang
Journal:  Oncol Lett       Date:  2015-04-20       Impact factor: 2.967

3.  Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.

Authors:  Taras G Balandin; Evelina Edelweiss; Natalia V Andronova; Elena M Treshalina; Alexander M Sapozhnikov; Sergey M Deyev
Journal:  Invest New Drugs       Date:  2009-09-30       Impact factor: 3.850

4.  Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells.

Authors:  Heidi Cecilie Larsen Spång; Ranveig Braathen; Bjarne Bogen
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

5.  Modern Technologies for Creating Synthetic Antibodies for Clinical application.

Authors:  S M Deyev; E N Lebedenko
Journal:  Acta Naturae       Date:  2009-04       Impact factor: 1.845

Review 6.  Leczyme: a new candidate drug for cancer therapy.

Authors:  Takeo Tatsuta; Shigeki Sugawara; Kohta Takahashi; Yukiko Ogawa; Masahiro Hosono; Kazuo Nitta
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

7.  Specific visualization of tumor cells using upconversion nanophosphors.

Authors:  E A Grebenik; A N Generalova; A V Nechaev; E V Khaydukov; K E Mironova; O A Stremovskiy; E N Lebedenko; A V Zvyagin; S M Deyev
Journal:  Acta Naturae       Date:  2014-10       Impact factor: 1.845

8.  Bioreactor-Based Tumor Tissue Engineering.

Authors:  A E Guller; P N Grebenyuk; A B Shekhter; A V Zvyagin; S M Deyev
Journal:  Acta Naturae       Date:  2016 Jul-Sep       Impact factor: 1.845

9.  Targeted Drug Delivery in Lipid-like Nanocages and Extracellular Vesicles.

Authors:  A V Sokolov; N N Kostin; L A Ovchinnikova; Y A Lomakin; A A Kudriaeva
Journal:  Acta Naturae       Date:  2019 Apr-Jun       Impact factor: 1.845

Review 10.  Barnase-Barstar Pair: Contemporary Application in Cancer Research and Nanotechnology.

Authors:  Olga Shilova; Polina Kotelnikova; Galina Proshkina; Elena Shramova; Sergey Deyev
Journal:  Molecules       Date:  2021-11-10       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.